Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
1
16.7%
招募中
3
50.0%
终止
2
33.3%
暂无批准数据
- Tango Therapeutics priced an upsized underwritten public offering expected to generate approximately $600 million in gross proceeds, up from the initially proposed $500 million. - The offering includes 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants for an additional 1,833,395 shares at $29.999 each. - J.P. Morgan, Leerink Partners, Cantor, and Stifel are serving as joint bookrunning managers, with closing anticipated on or about June 11, 2026. - The clinical-stage company leverages synthetic lethality to discover novel drug targets and develop next-generation precision medicines for cancer treatment.
- Tango Therapeutics has appointed Matthew Gall as Chief Financial Officer and Yen-Ching Chua as Chief Development Operations Officer effective June 1, 2026, along with Janice Kapty as SVP of Corporate Strategy and Project Leadership. - The leadership changes are strategically aligned to advance the company's precision oncology pipeline, particularly vopimetostat and TNG456, through complex global development pathways. - Despite strong recent stock performance with 81.44% returns over 30 days, the company trades at a premium P/S ratio of 47.8x compared to industry averages, raising valuation concerns. - The new appointments aim to reduce operational friction and tighten execution between science, operations, and financing as the company navigates ongoing losses and clinical development challenges.
- Tango Therapeutics appointed Dr. Malte Peters as President and CEO, replacing founding CEO Dr. Barbara Weber who transitions to Executive Chair. - The leadership change comes as the company's lead PRMT5 inhibitor vopimetostat prepares to enter registrational trials for pancreatic cancer in 2026. - Dr. Peters brings extensive late-stage clinical development experience, having previously led global regulatory approval of Monjuvi at MorphoSys AG. - The company maintains its 2026 clinical milestone guidance, including combination trial data and pivotal study initiation for vopimetostat.
- Tango Therapeutics raised $225 million through a combined public offering and private placement, with the public offering expected to generate approximately $210 million in gross proceeds. - The financing was led by prominent institutional investors including Farallon Capital Management, TCGX, and Balyasny Asset Management, demonstrating strong investor confidence in the company's precision oncology approach. - The company focuses on synthetic lethality principles to discover novel cancer targets, including expanding precision oncology into areas like tumor suppressor gene loss and immune evasion mechanisms. - Proceeds will support Tango's clinical-stage pipeline of next-generation precision cancer medicines targeting critical vulnerabilities in cancer cells.
- Tango Therapeutics' lead candidate TNG462 has been granted Orphan Drug Designation by the FDA for pancreatic cancer treatment, providing seven years of market exclusivity upon approval. - The company's second PRMT5 inhibitor, TNG456, received FDA clearance for its IND application and will begin Phase 1/2 trials in early 2025, including a collaboration with Eli Lilly combining it with Verzenio. - Key clinical data for TNG462 monotherapy focusing on pancreatic and lung cancers is expected later in 2025, with plans to initiate a registrational study in pancreatic cancer by 2026.
• Tango Therapeutics' TNG462 demonstrates clinical activity in NSCLC and pancreatic cancer, with a 43% ORR in cholangiocarcinoma, showcasing a favorable safety profile. • Tango plans to initiate combination trials of TNG462 with RAS(ON) inhibitors from Revolution Medicines, osimertinib, and pembrolizumab in 1H 2025. • TNG908 shows clinical activity in non-CNS cancers, particularly pancreatic cancer, but development is deprioritized in favor of TNG462 due to its superior profile. • Tango's next-generation brain-penetrant PRMT5 inhibitor, TNG456, is set to begin phase 1/2 trials in 1H 2025, targeting glioblastoma and brain metastases.
- Tango Therapeutics has dosed the first patient in a phase 1/2 clinical trial of TNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor targeting MTAP-deleted solid tumors. - MTAP deletions occur in 10-15 percent of solid tumors and currently have no FDA-approved treatments specifically designed for this genetic alteration. - TNG462 selectively targets cancer cells with MTAP deletion while sparing normal cells, and demonstrated deep tumor regressions in preclinical models across multiple cancer types. - The company is also advancing TNG908, a brain-penetrant PRMT5 inhibitor, in a separate ongoing phase 1/2 study to address a broader range of indications.
